Leading pharma giant Dr Reddy’s has collaborated with the Russia Direct Investment Fund (RDIF) to facilitate the importing of the Sputnik V vaccine to India and other countries. The Russian-made vaccine has reportedly found to be equally effective for all age groups. It could be the third vaccine available in the nation after covaxin and Covishield.
“We expect to get the approval in the next few weeks. It is a two-dose vaccine. You take the first dose on day zero and the second one on day 21. The peak immunity develops somewhere between day 28 to day 42. So, it is a two-dose vaccine and we expect it to be available in the next few weeks,” Deepak Sapra, the company’s CEO, APIs and Services.
Sapra, who was interacting in a webinar on Wednesday evening, was questioned when Sputnik would be available and whether it is a one-dose or two doses vaccine.
Based on the data of preliminaries of the vaccine that have been held in Russia, India, the UAE and others, he said the Covid-19 immunization showed a viability of 91.6%. The information on trials is as of now with the Indian drug controller and the firm anticipates that it should get endorsed in the couple of weeks, he added.